CCTC TRANSPLANT PHARMACOLOGY EXAM / APPROVED CCTC
TRANSPLANT PHARMACOLOGY EXAM TESTBANK 2026/2027
PRACTICE QUESTIONS AND STUDY GUIDE ACCURATE EXAM
COMPLETE REAL QUESTIONS AND CORRECT VERIFIED
SOLUTIONS WITH RATIONALES (DETAILED ANSWERS) LATEST
UPDATED VERSION 2026 EDITION|GUARANTEED PASS A+ |JUST
RELEASED |INSTANT DOWNLOAD PDF
1. A 45-year-old male patient who underwent a living-donor renal
transplant 5 days ago presents with a serum creatinine level that has
risen from 1.2 mg/dL to 2.5 mg/dL over the past 48 hours. His urine
output has decreased, and he reports mild graft-site tenderness. A renal
biopsy is performed. What is the most likely pharmacological strategy to
manage his condition if the biopsy confirms acute T-cell mediated
rejection (TCMR), Banff grade IIA?
A. Administer a three-day course of high-dose oral prednisone
B. Administer a single dose of rituximab
C. Administer pulse-dose intravenous methylprednisolone for 3-5 days
→ CORRECT ANSWER
D. Increase the daily dose of his maintenance tacrolimus
RATIONALE: First-line treatment for acute TCMR, particularly Banff
grade IIA (moderate to severe), is pulse-dose intravenous corticosteroids
(methylprednisolone 500-1000 mg/day for 3-5 days) . This rapidly
reduces T-cell infiltration and inflammation. Oral prednisone is
insufficient for moderate-to-severe rejection, and rituximab is primarily
used for antibody-mediated rejection (AMR). Simply increasing
,tacrolimus is not the standard acute intervention for established
rejection.
2. Which of the following calcineurin inhibitor (CNI) drug pairs
correctly matches the medication with its primary mechanism of action
and major dose-limiting toxicity?
A. Tacrolimus: Inhibition of calcineurin leading to decreased T-cell IL-2
production; Nephrotoxicity → CORRECT ANSWER
B. Cyclosporine: Inhibition of mTOR leading to decreased T-cell
proliferation; Neurotoxicity
C. Tacrolimus: Inhibition of JAK3 leading to decreased cytokine
signaling; Hypertension
D. Cyclosporine: Inhibition of calcineurin leading to decreased B-cell
antibody production; Hyperlipidemia
RATIONALE: Tacrolimus and cyclosporine both inhibit calcineurin,
preventing NFAT dephosphorylation and subsequent IL-2 gene
transcription, thus inhibiting T-cell activation . Nephrotoxicity is the
major dose-limiting toxicity for both CNIs. mTOR inhibitors like
sirolimus are associated with hyperlipidemia, and JAK3 inhibition is the
mechanism of tofacitinib.
3. A patient is prescribed mycophenolate mofetil (MMF) as part of a
triple immunosuppressive regimen after a kidney transplant. Which of
the following drug-drug interactions would require a significant dose
reduction of MMF or close therapeutic drug monitoring?
,A. Coadministration with amoxicillin
B. Coadministration with acyclovir
C. Coadministration with ganciclovir → CORRECT ANSWER
D. Coadministration with ciprofloxacin
RATIONALE: Mycophenolic acid (MPA) and ganciclovir (or its
prodrug valganciclovir) both undergo enterohepatic recirculation and
compete for renal tubular secretion. Coadministration significantly
increases MPA and ganciclovir levels, increasing the risk of
myelosuppression (leukopenia, anemia, thrombocytopenia) . The dose of
both drugs must be carefully adjusted, especially in renal dysfunction.
4. A 60-year-old female underwent an orthotopic heart transplant 6
months ago. Her maintenance immunosuppression includes
cyclosporine, MMF, and prednisone. She is started on amiodarone for
new-onset atrial fibrillation. What is the most critical pharmacokinetic
interaction to monitor?
A. Amiodarone increases the hepatic clearance of cyclosporine
B. Amiodarone inhibits CYP3A4, leading to increased cyclosporine
levels and nephrotoxicity → CORRECT ANSWER
C. Amiodarone and cyclosporine compete for renal excretion
D. Amiodarone induces P-glycoprotein, leading to decreased
cyclosporine absorption
, RATIONALE: Amiodarone is a potent inhibitor of CYP3A4, the
primary metabolic pathway for both cyclosporine and tacrolimus.
Coadministration can dramatically increase CNI blood concentrations,
leading to severe nephrotoxicity and neurotoxicity. Cyclosporine levels
should be reduced by ~25-50% and monitored frequently when
amiodarone is initiated.
5. A lung transplant recipient develops a tremor and new-onset
hypertension. His tacrolimus trough level is 18 ng/mL (target 10-15
ng/mL). Which of the following pharmacogenetic factors could explain
his elevated trough level despite taking a standard weight-based dose?
A. CYP2C19 poor metabolizer phenotype
B. CYP3A5*3/*3 genotype (nonexpresser) → CORRECT ANSWER
C. CYP2D6 ultrarapid metabolizer phenotype
D. ABCB1 (P-glycoprotein) high-expresser genotype
RATIONALE: Tacrolimus is primarily metabolized by CYP3A4 and
CYP3A5. Individuals with the CYP3A5*3/*3 genotype are non-
expressers of functional CYP3A5, leading to significantly higher
tacrolimus blood concentrations per weight-based dose. Patients
expressing CYP3A5 (CYP3A5*1 carriers) require higher doses.
CYP2C19 and CYP2D6 are not major pathways for tacrolimus
metabolism.
6. The primary target of lymphocyte-depleting induction therapy agents
such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab is:
TRANSPLANT PHARMACOLOGY EXAM TESTBANK 2026/2027
PRACTICE QUESTIONS AND STUDY GUIDE ACCURATE EXAM
COMPLETE REAL QUESTIONS AND CORRECT VERIFIED
SOLUTIONS WITH RATIONALES (DETAILED ANSWERS) LATEST
UPDATED VERSION 2026 EDITION|GUARANTEED PASS A+ |JUST
RELEASED |INSTANT DOWNLOAD PDF
1. A 45-year-old male patient who underwent a living-donor renal
transplant 5 days ago presents with a serum creatinine level that has
risen from 1.2 mg/dL to 2.5 mg/dL over the past 48 hours. His urine
output has decreased, and he reports mild graft-site tenderness. A renal
biopsy is performed. What is the most likely pharmacological strategy to
manage his condition if the biopsy confirms acute T-cell mediated
rejection (TCMR), Banff grade IIA?
A. Administer a three-day course of high-dose oral prednisone
B. Administer a single dose of rituximab
C. Administer pulse-dose intravenous methylprednisolone for 3-5 days
→ CORRECT ANSWER
D. Increase the daily dose of his maintenance tacrolimus
RATIONALE: First-line treatment for acute TCMR, particularly Banff
grade IIA (moderate to severe), is pulse-dose intravenous corticosteroids
(methylprednisolone 500-1000 mg/day for 3-5 days) . This rapidly
reduces T-cell infiltration and inflammation. Oral prednisone is
insufficient for moderate-to-severe rejection, and rituximab is primarily
used for antibody-mediated rejection (AMR). Simply increasing
,tacrolimus is not the standard acute intervention for established
rejection.
2. Which of the following calcineurin inhibitor (CNI) drug pairs
correctly matches the medication with its primary mechanism of action
and major dose-limiting toxicity?
A. Tacrolimus: Inhibition of calcineurin leading to decreased T-cell IL-2
production; Nephrotoxicity → CORRECT ANSWER
B. Cyclosporine: Inhibition of mTOR leading to decreased T-cell
proliferation; Neurotoxicity
C. Tacrolimus: Inhibition of JAK3 leading to decreased cytokine
signaling; Hypertension
D. Cyclosporine: Inhibition of calcineurin leading to decreased B-cell
antibody production; Hyperlipidemia
RATIONALE: Tacrolimus and cyclosporine both inhibit calcineurin,
preventing NFAT dephosphorylation and subsequent IL-2 gene
transcription, thus inhibiting T-cell activation . Nephrotoxicity is the
major dose-limiting toxicity for both CNIs. mTOR inhibitors like
sirolimus are associated with hyperlipidemia, and JAK3 inhibition is the
mechanism of tofacitinib.
3. A patient is prescribed mycophenolate mofetil (MMF) as part of a
triple immunosuppressive regimen after a kidney transplant. Which of
the following drug-drug interactions would require a significant dose
reduction of MMF or close therapeutic drug monitoring?
,A. Coadministration with amoxicillin
B. Coadministration with acyclovir
C. Coadministration with ganciclovir → CORRECT ANSWER
D. Coadministration with ciprofloxacin
RATIONALE: Mycophenolic acid (MPA) and ganciclovir (or its
prodrug valganciclovir) both undergo enterohepatic recirculation and
compete for renal tubular secretion. Coadministration significantly
increases MPA and ganciclovir levels, increasing the risk of
myelosuppression (leukopenia, anemia, thrombocytopenia) . The dose of
both drugs must be carefully adjusted, especially in renal dysfunction.
4. A 60-year-old female underwent an orthotopic heart transplant 6
months ago. Her maintenance immunosuppression includes
cyclosporine, MMF, and prednisone. She is started on amiodarone for
new-onset atrial fibrillation. What is the most critical pharmacokinetic
interaction to monitor?
A. Amiodarone increases the hepatic clearance of cyclosporine
B. Amiodarone inhibits CYP3A4, leading to increased cyclosporine
levels and nephrotoxicity → CORRECT ANSWER
C. Amiodarone and cyclosporine compete for renal excretion
D. Amiodarone induces P-glycoprotein, leading to decreased
cyclosporine absorption
, RATIONALE: Amiodarone is a potent inhibitor of CYP3A4, the
primary metabolic pathway for both cyclosporine and tacrolimus.
Coadministration can dramatically increase CNI blood concentrations,
leading to severe nephrotoxicity and neurotoxicity. Cyclosporine levels
should be reduced by ~25-50% and monitored frequently when
amiodarone is initiated.
5. A lung transplant recipient develops a tremor and new-onset
hypertension. His tacrolimus trough level is 18 ng/mL (target 10-15
ng/mL). Which of the following pharmacogenetic factors could explain
his elevated trough level despite taking a standard weight-based dose?
A. CYP2C19 poor metabolizer phenotype
B. CYP3A5*3/*3 genotype (nonexpresser) → CORRECT ANSWER
C. CYP2D6 ultrarapid metabolizer phenotype
D. ABCB1 (P-glycoprotein) high-expresser genotype
RATIONALE: Tacrolimus is primarily metabolized by CYP3A4 and
CYP3A5. Individuals with the CYP3A5*3/*3 genotype are non-
expressers of functional CYP3A5, leading to significantly higher
tacrolimus blood concentrations per weight-based dose. Patients
expressing CYP3A5 (CYP3A5*1 carriers) require higher doses.
CYP2C19 and CYP2D6 are not major pathways for tacrolimus
metabolism.
6. The primary target of lymphocyte-depleting induction therapy agents
such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab is:
